ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses2.06 M2.87 M2.68 M1.64 M4.39 M11.57 MResearch & development——————Operating income-4.01 M-13.33 M-3 M-5.85 M-8.61 M-30.79 MNon-Operating Income, Total2.92 M—————Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses2.92 M—————Unusual income/expense——————Pretax income23.97 M19.81 M-3 M-5.85 M-8.61 M2.36 MEquity in earnings—0————Taxes12 K63 K03 000066 KNon-controlling/minority interest——————After tax other income/expense—2 000————Net income before discontinued operations23.98 M19.73 M54.15 M26.64 M146.34 M246.87 MDiscontinued operations—0————Net income23.98 M19.73 M54.15 M26.64 M146.34 M246.87 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders23.98 M19.73 M54.15 M26.64 M325.34 M425.87 MBasic earnings per share (Basic EPS)-0.09-0.05-0.18-0.09-1.06-1.38Diluted earnings per share (Diluted EPS)-0.09-0.05-0.18-0.09-1.06-1.38Average basic shares outstanding275.88 M267.73 M293.88 M296.43 M307.17 M1.17 BDiluted shares outstanding275.88 M267.73 M293.88 M296.43 M307.17 M1.17 BEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)674 K661 K629 K630 K803 K2.72 M
Precigen Inc
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.